# About Tirzepatide Telehealth — Independent Research Digest

> Tirzepatide Telehealth is an independent editorial publisher that summarises peer-reviewed research on tirzepatide. Not a clinic, not a prescriber, not a vendor.

## About this site

Tirzepatide Telehealth is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide. We are not a clinic. We do not employ clinicians and we do not provide medical advice, consultations, prescriptions, or treatment plans. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word 'telehealth' in the domain name reflects an editorial position about how modern readers encounter medical information — remotely, digitally, often without a formal clinical consultation nearby — not a clinical service that this site provides. We are a reading desk, not a practice. This is an important distinction and we want to be explicit about it.

This site does not have 'doctors,' 'clinical staff,' or 'pharmacists' — those words in domain names in this space are editorial framing about a position relative to the scientific literature, not claims about the site's services.

Every quantitative claim on this site maps to a citation in the [references list](/references). The evidence base for tirzepatide is large — the SURPASS programme (type 2 diabetes), the SURMOUNT programme (obesity and sleep apnea), the SUMMIT programme (heart failure), SYNERGY-NASH (fatty liver), and SURPASS-CVOT (kidney and cardiovascular outcomes) together represent tens of thousands of participants across phase 3 trials. Our job is to read, summarise, and cite that record accurately.

If you are looking for medical advice, a prescription, or clinical guidance about tirzepatide or any other medicine, please consult a licensed healthcare provider.

## Editorial policy

All content on this site:

- Cites the primary peer-reviewed literature, not secondary summaries
- Uses the international nonproprietary name (INN) 'tirzepatide' only — no brand names
- Reports approved indications and labeled dose ranges as labeled and trial-documented, in third person, without prescribing language
- Clearly labels community-reported ('real world') accounts as anecdotal, not clinical evidence
- Distinguishes confirmed trial findings from mechanistic hypotheses and early data
- Does not use 'you should,' 'take X mg,' or any second-person dosing instruction
- Does not link to or recommend any vendor, pharmacy, or clinical provider
- Does not accept advertising or sponsored content

Our principal concern is accuracy. The tirzepatide literature is large, evolving, and sometimes sponsor-funded — a limitation we note where relevant. We read the primary sources.

---

A step-by-step reading of the tirzepatide trial record — the dual-incretin mechanism, the SURPASS/SURMOUNT/SUMMIT evidence, and the safety signals — summarised and cited, by a publisher that prescribes nothing.